Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

National Cancer Institute (NCI)

Funding Opportunity Title
Limited Competition: Childhood Cancer Survivor Study (U24 Clinical Trial Required)
Activity Code

U24 Resource-Related Research Projects – Cooperative Agreements

Announcement Type

Reissue of RFA-CA-15-502 - Limited Competition: Childhood Cancer Survivor Study (U24)

Related Notices

  • October 7, 2020 - Notice of Correction to RFA-CA-20-052. See Notice NOT-CA-21-005.

Funding Opportunity Announcement (FOA) Number
Companion Funding Opportunity


Catalog of Federal Domestic Assistance (CFDA) Number(s)


Funding Opportunity Purpose

The purpose of this limited competition Funding Opportunity Announcement (FOA) is to continue support for the Childhood Cancer Survivor Study (CCSS) as a resource enabling broad studies on the long-term effects of cancer and its associated therapies on survivors of pediatric and adolescent cancers. CCSS is a multi-institutional collaborative project that supports a participant cohort of over 25,000 five-year survivors of childhood cancer diagnosed between 1970-1999 and over 5,000 sibling control subjects.

Key Dates

Posted Date
August 13, 2020
Open Date (Earliest Submission Date)
October 18, 2020
Letter of Intent Due Date(s)

30 days prior to the application due date

Application Due Date(s)

November 18, 2020

No late applications will be accepted for this FOA.

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s)

Not Applicable



Scientific Merit Review

March/April 2021

Advisory Council Review

May 2021

Earliest Start Date

December 2021

Expiration Date
November 19, 2020
Due Dates for E.O. 12372

Not Applicable

Required Application Instructions

It is critical that applicants follow the instructions in the Research (R) Instructions in the SF424 (R&R) Application Guide,except where instructed to do otherwise (in this FOA or in a Notice from NIH Guide for Grants and Contracts ).

Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.

Applications that do not comply with these instructions may be delayed or not accepted for review.

Table of Contents

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description


The purpose of this limited competition Funding Opportunity Announcement (FOA) is to continue the Childhood Cancer Survivor Study (CCSS). CCSS is a multi-institutional collaborative endeavor to assemble and maintain a research cohort of over 35,000 eligible five-year survivors of childhood cancer evaluable for late mortality studies and over 25,000 participants(14,000 diagnosed between 1970-1986 and 11,000 diagnosed between 1987 and 1999). Over 5000 siblings participate as control subjects. CCSS has established itself as the national resource for research on late effects and ongoing risks in survivors of childhood and adolescent cancer.

The CCSS awardees seeking renewal of this research resource are expected to address the following important research directions and specific objectives:

  • Maintenance and enhancement of CCSS as a resource;
  • Provide plans for gathering data during the funding period that will be used to develop a strategic plan to, in the future, recruit a new cohort of patients diagnosed between 2000-2020. The composition of the cohort should include patients treated with novel therapies as well as appropriate controls and siblings. The characteristics of the plan should describe projected prospective power analyses based on real patient numbers to verify that the composition of any future expansion of CCSS will be of scientific value and lend itself to addressing scientific questions;
  • Develop, implement and test clinical models for precision prevention of late effects;
  • Stimulate and facilitate research using phenotypic, genotypic and outcome data from CCSS participants;
  • Develop and implement intervention studies utilizing new approaches such as mHealth;
  • Incorporation of CCSS-driven research into the COG Late Effects Guidelines and pediatric PDQ statement on late effects;
  • Evaluate the impact of risk stratification of therapy on the pattern of late effects
  • Foster electronic engagement of the cohort and develop new strategies of engagement
  • Expansion of scientific discipline expertise within the leadership for specific areas such as Aging and Health Services;
  • Exploit CCSS to investigate the outcome of survivors of adolescent and young adult cancers;
  • Utilize CCSS to address questions of impact of ethnic/racial diversity on survivor outcome;
  • Develop and conduct directed, hypothesis-testing molecular genetic studies that utilize the biologic materials collected and stored within CCSS;
  • Enhance the accessibility of all CCSS data (phenotypic and genotypic) so it will be available for all investigators;
  • Develop a fast track approach for investigators using CCSS for grant applications and not requiring CCSS statistical assistance;
  • Collaborate with other childhood cancer survivor groups internationally to validate genomic studies, risk prediction models, address novel questions pertaining to access to care, screening and harmonization of long-term guidelines for childhood cancer survivors;
  • Continued development of strategies by organ systems to investigate late effects in childhood cancer survivors and translation into clinical research;
  • Identification and characterization of ancillary studies utilizing the CCSS database and biospecimens that have resulted in NIH funding and/or publications;
  • Continue to support and enhance investigations with available resources involving CCSS for all investigators (young investigators, new investigators and more experienced investigators);
  • Successful mentorship as assessed by completion of trainee proposed projects that have been published or used as a basis for a grant;
  • Continued education and communication with the participants of CCSS of the research findings; and
  • Presentations of Working Group projects and individual research projects utilizing the CCSS cohort at national meetings and publications in peer-reviewed journals.


As a result of improvements in childhood cancer therapy over the past 5 decades, more than 80% of children and adolescents diagnosed with cancer will experience long-term survival into adulthood. Through the CCSS, which has been funded by the NCI since 1993, investigators have identified and characterized the spectrum of adverse outcomes that long-term survivors are at risk of developing. The results of the CCSS have greatly advanced knowledge of late effects among survivors of pediatric cancer. Researchers have demonstrated that 60-90% of adults treated for cancer during childhood develop one or more chronic health conditions. They have also shown that by age 50 years, the cumulative incidence of self-reported severe, disabling, life-threatening, or fatal health condition was 53.6% among survivors compared with 19.8% among sibling control group. Among childhood cancer survivors who reach age 35 years without a previous severe, disabling, life-threatening, or fatal health condition, 25.9% will experience a new severe, disabling, life-threatening or fatal condition within 10 years as compared to 6% of healthy siblings. In addition to the findings related to an increased risk of increased morbidity and mortality, CCSS has shown that long-term survivors are at risk of developing a variety of adverse outcomes which include subsequent malignancies, organ dysfunction (e.g., cardiac, pulmonary, gonadal), impaired growth and development, impaired cognitive function, difficulties obtaining employment and insurance, and compromises in the quality of life. Many of these long-term effects and how they affect survivors are poorly understood. Identification of individuals predisposed to develop these long-term effects and interventions designed to ameliorate these negative consequences of cancer treatment are ongoing. CCSS provides the foundation for these additional investigations. Based on the successful establishment of the unique CCSS cohort and its contributions to the area of cancer survivorship, CCSS has become an important resource to the cancer research community as evidenced by the more than 370 publications from greater than 700 investigators. Recognizing the CCSS research contributions, the NCI intends to continue supporting this program as defined by this FOA.

Continuing the research activities of the longest followed cohort of childhood cancer survivors through CCSS and supporting the banking of germline DNA and tissue from subsequent neoplasms will broaden the resource for all investigators to study, predict and potentially intervene in the late effects of treatment for survivors of childhood and adolescent cancer. Research results from CCSS will help cancer survivors to have the optimal quality of life and inform their physicians on how to provide the highest quality of care. In addition, these findings serve to inform and modify current and future treatment approaches for children and adolescents with cancer.

Overall Objectives for CCSS

The overall objectives of CCSS are to quantify and better understand the effects of pediatric cancer and its treatment on later health, including aging, behavioral, sociodemographic outcomes and relationships with genetic factors and Health Services.

The emphasis of the CCSS is on approaches to ensure the functioning of CCSS as a strong and productive resource for researchers studying pediatric cancer survivors diagnosed between 1970 -1999 and their siblings.

Additional priorities are to enhance the CCSS resource by increasing the capacity to conduct hypothesis-testing Aging and Health Services research as well as genetic-based research, and to enhance the use of CCSS data, expertise, and tissue samples. In this context, it is expected that the renewed CCSS will serve:

  • Investigators involved with CCSS Working Groups formed to focus on specific research topics and directed to answer research questions in prioritized areas of interest to CCSS; and
  • Investigators interested in utilizing the CCSS resources for their externally funded research projects.

Secondary goals/areas of emphasis for the program include:

  • Providing plans for gathering data during the upcoming funding period that will be used to develop a strategic plan to, in the future, recruit a new cohort of patients diagnosed between 2000-2020 that will include participants receiving novel therapies;
  • Evaluating physiologic, neurocognitive aging and underlying mechanisms of accelerated aging in the cohort;
  • Enhancing the cohort to better facilitate conduct of Health Services research
  • Facilitating studies utilizing genomic data from the CCSS cohort, and expand capability for data sharing for collaboration with other cohorts;
  • Promoting precision prevention by developing clinical risk prediction tools;
  • Building the capacity to facilitate translation of CCSS findings and identify the opportunities for intervention strategies including mHealth approaches (however, the actual conduct of intervention studies remain beyond the scope of this FOA);
  • Developing strategies to improve the understanding of late effects on survivor health by specific organ system;
  • Identifying and collaborating with other childhood cancer survivor groups internationally;
  • Enhancing the research experience for all investigators; Develop a "fast track" for approval of projects when the investigator is applying for a grant and will not require a dataset from the CCSS or statistical assistance;
  • Introducing young/new investigators to CCSS and providing mentorship and tracking outcomes of their projects and involvement; and
  • Establish a NIH compliant data sharing platform that will make all CCSS data, both clinical and genomic (appropriately de-identified), readily available to all investigators.

To address the stated goals and priorities, CCSS will be expected to have appropriate leadership, organization, and capabilities to ensure a smooth integration of the cohort-related functions, as specified in Section IV of this FOA, under Research Strategy

Organizational Requirements and Expectations

To conduct the indicated Research Programs of CCSS, the applicant is expected to assemble (or continue) a consortium of multiple collaborating institutions and researchers with appropriate expertise and interest in childhood cancer survivorship, who provide the access to the needed patient populations as appropriate to support the goals of the CCSS.

Leadership Structure

It is expected that the scientific leadership will reflect the scientific disciplines of the CCSS and will continue to use Working Groups consisting of investigators with survivorship expertise to prioritize research areas of particular interest to CCSS.

Required Functionalities

The CCSS must provide appropriate functionalities (referred to as "support units") in specific areas as outlined below.

  • Administrative support must be organized to serve overall administrative and organizational needs of the entire CCSS. The CCSS administrative support is expected to function as a central office, located at the lead PD/PI’s institution. In addition to internal CCSS administration, the administrative support must serve the interactions between CCSS investigators and the Steering Committee and the NCI.
  • Radiation physicists must be capable of reviewing all relevant radiation therapy records for survivors who received radiation therapy.
  • Biopathology group will be responsible for collecting the tissue from all subsequent malignant neoplasms occurring in participants in the CCSS in order to identify, confirm, and analyze the neoplasms.
  • Biorepository group (Molecular Genetic Bank) must be organized to continue to collect and bank the genomic DNA obtained from peripheral blood, buccal cell or saliva samples of survivors and siblings, plus peripheral blood samples from survivors with a subsequent neoplasm.
  • Data and Statistics services must be able to ensure accuracy in collection and management of the data in the CCSS study. This group will provide biostatistical support to the majority of CCSS data-analysis projects.

Overall governance of the CCSS program. The Steering Committee will serve as the main governing board for CCSS. For details see Section VI.2. Cooperative Agreement Terms and Conditions of Award of this FOA.

See Section VIII. Other Information for award authorities and regulations.

Section II. Award Information

Funding Instrument

Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this FOA.

Application Types Allowed

The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. Only those application types listed here are allowed for this FOA.

Clinical Trial?
Required: Only accepting applications that propose clinical trial(s)

Need help determining whether you are doing a clinical trial?

Funds Available and Anticipated Number of Awards

NCI intends to commit ~$2.74 million in direct costs in FY 2022 to fund one award.

Award Budget

Application budget is not limited but needs to reflect the actual needs of the proposed project and must not exceed $2,742,237 /year (direct costs) and $13,711,185 (direct costs) over 5 years.

Award Project Period

5 years

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this FOA.

Section III. Eligibility Information

1. Eligible Applicants

Eligible Organizations

Higher Education Institutions

  • Public/State Controlled Institutions of Higher Education
  • Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

  • Hispanic-serving Institutions
  • Historically Black Colleges and Universities (HBCUs)
  • Tribally Controlled Colleges and Universities (TCCUs)
  • Alaska Native and Native Hawaiian Serving Institutions
  • Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

Nonprofits Other Than Institutions of Higher Education

  • Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
  • Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

  • Small Businesses
  • For-Profit Organizations (Other than Small Businesses)

Local Governments

  • State Governments
  • County Governments
  • City or Township Governments
  • Special District Governments
  • Indian/Native American Tribal Governments (Federally Recognized)
  • Indian/Native American Tribal Governments (Other than Federally Recognized)


  • Independent School Districts
  • Public Housing Authorities/Indian Housing Authorities
  • Native American Tribal Organizations (other than Federally recognized tribal governments)
  • Faith-based or Community-based Organizations
  • Regional Organizations

Only the current recipients of the CCSS award are eligible to apply.

It is expected that the subcontracting institutions on the current award will continue their participation in CCSS. However, it is up to the applicant team to determine the final composition of the collaborating institutions.

Foreign Institutions

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed. 

Required Registrations

Applicant organizations

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.

  • Dun and Bradstreet Universal Numbering System (DUNS) - All registrations require that applicants be issued a DUNS number. After obtaining a DUNS number, applicants can begin both SAM and eRA Commons registrations. The same DUNS number must be used for all registrations, as well as on the grant application.
  • System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
  • eRA Commons - Applicants must have an active DUNS number to register in eRA Commons. Organizations can register with the eRA Commons as they are working through their SAM or registration, but all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
  • – Applicants must have an active DUNS number and SAM registration in order to complete the registration.

Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account.  PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

2. Cost Sharing

This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

3. Additional Information on Eligibility

Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time.  This means that the NIH will not accept:

  • A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
  • A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
  • An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101)

Section IV. Application and Submission Information

1. Requesting an Application Package

The application forms package specific to this opportunity must be accessed through ASSIST, Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Workspace are available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

2. Content and Form of Application Submission

It is critical that applicants follow the instructions in the Research (R) Instructions in the SF424 (R&R) Application Guide except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

Letter of Intent

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.

By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:

  • Descriptive title of proposed activity
  • Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)
  • Names of other key personnel
  • Participating institution(s)
  • Number and title of this funding opportunity

The letter of intent should be sent to:

Nita L. Seibel, M.D.
National Cancer Institute (NCI)
Telephone: 240-276-6078

Page Limitations

All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed,

with the following exceptions or additional requirements:

  • For this specific FOA, the Research Strategy section is limited to 30 pages.
Instructions for Application Submission

The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.

SF424(R&R) Cover

All instructions in the SF424 (R&R) Application Guide must be followed.

SF424(R&R) Project/Performance Site Locations

All instructions in the SF424 (R&R) Application Guide must be followed.

SF424(R&R) Other Project Information

All instructions in the SF424 (R&R) Application Guide must be followed.

Other Attachments: Provide the following materials listed below as Other Attachments. Upload these items as indicated attachments using file names provided (these file names will become bookmarks in the application).

  • Attachment 1 (filename Cohort & Research Highlights):
  • A summary table(s) of the main characteristics of the CCSS cohort including subgroup representation (e.g. minorities, adolescents etc.);
  • A figure(s) or table(s) showing the changes in treatment modalities over time for the CCSS cohort;
  • A summary of surveys and investigator-initiated grants, e.g., a figure(s) showing the timing of the CCSS surveys and the investigator initiated projects with grant support using CCSS;
  • Characteristics of CCSS genetic resource (in tabular format)
  • Summary of the research impact of CCSS, e.g., a table(s) showing selective examples of innovative, high impact research using CCSS; and
  • Impact on clinical practice (a table listing examples of CCSS publications informing the most recent COG Late Effect Guidelines).
  • Attachment 2 (filename Organizational Structure):
  • A chart illustrating the organizational and leadership structure of CCSS;
  • Attachment 3 (filename Biospecimens Distribution):
  • A table listing subsequent neoplasms reported from the CCSS cohort and specimen collection; and
  • A table listing the datasets distributed for the past 5 years to investigators (include information (columns) on whether the datasets needed revision or clean up and response time to investigators for receipt of dataset from project approval date).
  • Attachment 4 (filename Timeline):
  • The timeline for future objectives/benchmarks for CCSS (a figure or a diagram)
SF424(R&R) Senior/Key Person Profile

All instructions in the SF424 (R&R) Application Guide must be followed.

Applicants are encouraged to designate a contact PD/PI (based in the application submitting institution) and a second PD/PI, who would share the responsibilities but would also be capable of leading the entire CCSS (in case the lead PD/PI is unable to continue serving in this role). If only one PD/PI is designated, applicants must identify a PD/PI potential replacement candidate, i.e., a senior investigator who will be qualified to take over the PD’s/PI’s responsibility for the entire CCSS if such need arises.

R&R Budget

All instructions in the SF424 (R&R) Application Guide must be followed.

$100,000 per year should be set aside for pilot projects to be initiated post-award. These reserved funds can be used only for the pilot projects that are approved for funding by the CCSS Steering Committee.

R&R Subaward Budget

All instructions in the SF424 (R&R) Application Guide must be followed.

PHS 398 Cover Page Supplement

All instructions in the SF424 (R&R) Application Guide must be followed.

PHS 398 Research Plan

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:

Research Strategy: The Research Strategy must consist of sub-sections A-F as defined below.

Sub-section A. CCSS Overview

In this section, address the following aspects.

Describe the history and experience of the applicants' team in designing and implementing the CCSS. Outline the scientific rationale underpinning the need for the cohort. Address the following specific aspects.

  • Cohort Characteristics: Summarize the main characteristics of the cohort (diagnosed 1970-1999), including a breakdown by gender and racial/ethnic subpopulations. Update on the progress with the merged cohort, including identification and recruitment of study subjects and expanded sibling population.
  • CCSS Significance and Overall Goals: Summarize the main scientific and public health-related benefits anticipated from the continuation of the CCSS resource, justification for expansion cohort and significance of CCSS in terms of risk identification for cancer survivorship and impact of CCSS on survivorship research. Summarize the CCSS's role and potential relative to mortality, morbidity, and quality of life of long-term survivors of childhood cancer with illustrative examples.
  • Progress Report: Summarize the main accomplishments of the CCSS during the current funding period; include information on establishment, maintenance, and enhancement of the resource; salient contributions to peer-reviewed literature; and CCSS functioning as a resource for investigator-initiated research supported by external grants.

Note: Supplementary data in support of this subsection are requested under Other Attachments as Attachment 1.

Sub-section B. Leadership and Administrative Functions

In this sub-section, address the following aspects.

  • Senior Leadership: Outline the proposed leadership structure (avoiding duplication with the "Multiple PD/PI Leadership Plan", if multiple PD/PI option is used). In addition to an overall PD/PI (expected to be designated as contact PD/PI at the application-submitting institution), identify another PD/PI (or a substitute PD/PI candidate) to assure program continuity. Without repeating information in respective biosketches, explain how the qualifications and experience of both persons would be advantageous for organizing and managing the CCSS and related activities as multi-institutional collaborative efforts. Describe the strategy to divide leadership responsibilities among key/senior individuals. List specific topical areas expected to be covered by CCSS Working Groups and individuals who will provide scientific leaderships for these Working Groups. Outline the roles and proposed duties of other key individuals in the leadership besides the PD(s)/PI(s) (for example, individuals who would lead support units defined below).
  • Administrative Functions: Explain the roles and responsibilities of a unit, which will be providing administrative services to CCSS and logistic support for the interactions among CCSS investigators, the Steering Committee, and the NCI. Identify an individual who will be primarily responsible for the administrative support. The administrative support must have appropriate capabilities to manage cohort communications as well as regulatory staff and other administrative staff, as needed (e.g., to administer surveys, informed consent, requests for medical record release and follow-up).

Note: Supplementary data in support of this subsection are requested under Other Attachments as Attachment 2.

Sub-section C. Specialized Functional Support Groups.

Provide details on the specialized groups needed to support the basic functions of CCSS. For each of these groups, identify the group leader(s) (if applicable) and outline how the group (or its prior equivalent) has contributed to the CCSS past performance. Outline planned activities of these groups using the guidelines provided below. When appropriate, address quality control issues.

It is expected that the following functional groups will be included.

  • Radiation physics group: This group will be expected to document absorbed radiation doses, specific to organs or anatomic sites for each individual included in a specific study, by merging basic dosimetry data and data concerning the individual's radiation treatment. Appropriate quality control techniques must be used to ensure correctness of dosimetry.
  • Biopathology group: In addition to collecting and reviewing the subsequent neoplasms, the biopathology group continues to collect retrospectively paraffin-embedded tumor material to create an archive for future studies. The description should include an update on collection, processing, and storage of biological specimens including sample management procedures.
  • Bio-repository group (Molecular Genetic Bank): Provide an update on collection, processing, and storage of biological specimens including sample management procedures. Since this is such a unique, valuable resource, the investigators should identify the strategies to protect and maintain the resource and perform quality control (including sample receipt and storage, verification of specimen identification, and appropriate de-identification of accompanying data, etc.). Personnel training in these areas should be outlined, as appropriate.
  • Data and Statistics group: CCSS statisticians should be involved in reviewing all requests for access to CCSS data to ensure sound statistical design and analysis consistent with the overall design of CCSS. The CCSS statisticians are also expected to review all manuscripts of scientific publications generated using CCSS data for accuracy, consistency, and appropriateness of method descriptions and data interpretation. CCSS statisticians and ancillary personnel will be expected to interact regularly with the CCSS leadership to discuss emerging issues associated with the data collection/management as well as study design and analytic issues relevant to ongoing data-analysis projects. Outline the priorities in these areas and explain rules and general procedures for curating datasets for release to external investigators (including data cleaning/editing and quality control for such actions). Develop timelines with milestones and projected time frames for approval, development, analysis and publication for research project utilizing CCSS datasets and show compliance with these timeframes. Develop a "fast track " procedure for investigators using CCSS data for grant submission and for investigators who have their own statistical support.

Note: Supplementary data in support of this subsection are requested under Other Attachments as Attachment 3.

Sub-section D. Program for Cohort Integration and Basic Resource Functions

In this section, address the following aspects.

  • Define the overall goals for cohort integration and basic functions;
  • Describe plans for surveillance and maintenance of the merged cohort including validation and quality control;
  • Outline long-range strategy for the use of CCSS data to facilitate conception, development, implementation, and conduct of future intervention studies (beyond the scope of this FOA);
  • Indicate specific opportunities/directions for such intervention studies inspired by CCSS findings;
  • Characterize approaches to communication, education, and maintenance of contacts with the study participants;
  • Although innovation is not essential for CCSS research, indicate any concepts, methodologies, and/or intervention options proposed that are novel to field of cancer survivorship;
  • Outline approaches to protecting subject privacy and confidentiality for study participants; and
  • Outline procedures to ensure that all participating clinical sites fully comply with all NIH and Federal Regulations in terms of protection of human subjects including IRB approvals, informed consent, and other required regulatory approval documents (avoid repetitions with the separate required Section of Research Plan, "Protection of Human Subjects").

Sub-section E. Internal Research (including Methodologic Research, if applicable)

  • Identify the investigators expected to lead the internal research.
  • Define the current overall research goals.
  • If methodologic research is proposed, it should be aimed at developing, testing, and validating new methods and approaches to improve the proposed cohort infrastructure.
  • Describe the general focus areas/research directions for research by investigators involved with CCSS Working Groups.
  • Describe how new research directions/projects will be initiated, reviewed, and prioritized for the final approval by the Steering Committee.
  • Describe how the genetic resources (data, biospecimens) accumulated through the Molecular Genetic Bank will be made available for all investigators.
  • Outline a strategy to use CCSS data to improve the understanding of late effects on survivors health by specific organ system.
  • Pilot projects for junior investigators: Explain the anticipated role of pilot projects in helping junior investigators in hypothesis-generating and hypothesis-testing studies. The goal is to facilitate generation of preliminary data that junior investigators could use to further develop competitive research directions for which, ultimately, an independent funding (e.g., R01 grants) would be sought. Do NOT propose any specific pilot projects in the application. Rather, provide details on how such pilot projects will be generated, evaluated, and prioritized. The plans should incorporate the expectation that the Steering Committee will be involved in the final approval of pilot projects for execution. A "junior" investigator is defined as an investigator at the level of Assistant Professor or lower when the pilot project funding begins.
  • Describe other activities oriented on engaging junior investigators at all CCSS-affiliated institutions in pediatric cancer survivorship research.

Note: Supplementary data in support of this subsection are requested under Other Attachments as Attachment 4.

Sub-Section F. Outreach and External Research

  • Describe the approaches to facilitate research by investigators not affiliated with any of the institutions forming the CCSS and outreach strategies to make the resource optimally available to interested scientists and efficiently disseminate the resulting findings to broad communities;
  • Identify the individual(s) primarily responsible for these activities.
  • Address priorities and focus areas that might be of interest to investigators not associated with CCSS Working Groups. Define the anticipated role of Working Groups in review of research proposed by all investigators.
  • Address approaches to increase the scientific and public visibility of the CCSS findings (notably including their impact on the Children's Oncology Group Late Effects Guidelines,
  • Outline existing and planned international collaborations with other childhood cancer survivor groups.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.

The following modifications also apply:

  • All applications, regardless of the amount of direct costs requested for any one year, should address a Sharing Data Plan.
  • In addition, the following should be addressed:
    • the extent and type of data that will be shared,
    • the data repository to which the data will be submitted (repository must be publicly accessible or controlled access, but is not limited to NIH repositories, see for a full listing of NIH repositories); If a public repository is used it should be in accordance with NIH/NCI expectations of broad accessibility (i.e. no embargo after publication, no fees for access, and independent data access decisions), and
    • the timeline for the data to be shared after each round of data acquisition.

The above criteria apply to data generated from all specimens (e.g. not limited to tissue samples and blood) collected through CCSS, independent of the funding support of the analyses.

Cohorts are required to maintain a website that details (preferably a tab on the website) the procedure for all investigators requesting and obtaining data; procedures and criteria for access must be compliant with NIH data sharing policies. Applicants are encouraged to consider NIH data repositories (such as dbGaP) for sharing data with investigators. A summary of the number of data requests, acceptances, and rejections should be provided in annual progress reports to NCI along with a timeline for specific milestones and the average time for investigators to meet these milestones. Resource sharing plans should follow the FAIR principles and be fully compliant with NIH policies

Processes described should not be limited to investigators who want to have a collaborative relationship with CCSS but also describe access to de-identified data (not just summary tables).


Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide

PHS Human Subjects and Clinical Trials Information

When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed.

Delayed Onset Study

Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start).All instructions in the SF424 (R&R) Application Guide must be followed.

PHS Assignment Request Form

All instructions in the SF424 (R&R) Application Guide must be followed.

Foreign Institutions

Foreign (non-U.S.) institutions must follow policies described in the NIH Grants Policy Statement, and procedures for foreign institutions described throughout the SF424 (R&R) Application Guide.

3. Unique Entity Identifier and System for Award Management (SAM)

See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and

4. Submission Dates and Times

Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.

Organizations must submit applications to (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to on or before the application due date and time.  If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

5. Intergovernmental Review (E.O. 12372)

This initiative is not subject to intergovernmental review.

6. Funding Restrictions

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement.

7. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide.  Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.

The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.

Post Submission Materials

Applicants are required to follow the instructions for post-submission materials, as described in the policy. Any instructions provided here are in addition to the instructions in the policy.

Section V. Application Review Information

1. Criteria

Only the review criteria described below will be considered in the review process.  Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.

For this particular announcement, note the following:

Merit assessment of the CCSS application will particularly emphasize the usefulness of this resource to the scientific community in terms of the ability to provide rigorous insights into late effects of treatment for childhood cancer and inspire strategies for alleviating these late effects. The overall impact of the entire CCSS will be assessed based on the likelihood that the resource will contribute significantly to the improvements in quality of life for pediatric cancer survivors.

Individual aspects identified under the five criteria below will be assessed collectively in the context of their optimization for this overarching goal.

In addition, for applications involving clinical trials: A proposed Clinical Trial application may include study design, methods, and intervention that are not by themselves innovative but address important questions or unmet needs. Additionally, the results of the clinical trial may indicate that further clinical development of the intervention is unwarranted or lead to new avenues of scientific investigation.

Overall Impact

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

Scored Review Criteria

Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.


Does the project address an important problem or a critical barrier to progress in the field? Is the prior research that serves as the key support for the proposed project rigorous? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

Specific to this FOA: As proposed, will the CCSS provide the anticipated benefits in terms of meaningful scientific insights that would be able to inspire strategies for alleviating the late effects of treatment for childhood cancer? Can the proposed CCSS maximize the usefulness of this resource to scientific community? What is the likelihood that the activities under the CCSS award will inspire the investigators and facilitate their attempts to leverage other resources towards additional goals (exceeding the required scope) that would enhance the potential impact of the resource (e.g., intervention studies, molecular genetic studies, etc.)?

In addition, for applications involving clinical trials: Are the scientific rationale and need for a clinical trial to test the proposed hypothesis or intervention well supported by preliminary data, clinical and/or preclinical studies, or information in the literature or knowledge of biological mechanisms? For trials focusing on clinical or public health endpoints, is this clinical trial necessary for testing the safety, efficacy or effectiveness of an intervention that could lead to a change in clinical practice, community behaviors or health care policy? For trials focusing on mechanistic, behavioral, physiological, biochemical, or other biomedical endpoints, is the trial needed to advance scientific understanding?


Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

In addition, for applications involving clinical trials: With regard to the proposed leadership for the project, do the PD/PI(s) and key personnel have the expertise, experience, and ability to organize, manage and implement the proposed clinical trial and meet milestones and timelines? Do they have appropriate expertise in study coordination, data management and statistics? For a multicenter trial, is the organizational structure appropriate and does the application identify a core of potential center investigators and staffing for a coordinating center?


Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

In addition, for applications involving clinical trials: Does the design/research plan include innovative elements, as appropriate, that enhance its sensitivity, potential for information or potential to advance scientific knowledge or clinical practice?


Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators included plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?

Specific to this FOA:

  • Are the CCSS design and plans for administrative functions sufficient in terms of efficient support of CCSS activities across multiple participating institutions?
  • Are the organization, personnel, and procedures proposed for the specific Functional Support groups appropriate and well optimized? Are there appropriate plans for the sufficiently rigorous management (including quality control) of data and biospecimens collected by the CCSS?
  • Cohort Integration and Basic Resource Functions: Are the current CCSS cohorts adequate for the overall goals of the program? If the cohorts are not sufficiently representative, do the applicants address this issue and propose approaches to ameliorate the problem? Are the plans to maintain the merged cohort well thought out and sufficiently specific (e.g., with regard to maintaining contact with study participants, collecting outcome data, etc.)? How well do the proposed plans cover and track outcome variables that are critical for the goals of this FOA? Are the proposed approaches optimal and conducive to identifying important opportunities for future intervention studies?
  • Internal Research: Is the internal research agenda for CCSS well developed and responsive to the needs and expectations (e.g., in terms of sufficient focus on specific organ system, hypothesis-testing molecular genetic studies, engaging junior/new investigators, etc.)?
  • Outreach and External Research: Will all investigators have sufficient and easy access to the resource? Are appropriate measures proposed to ensure that all investigators utilizing the CCSS resources comply with the access/usage policies and rules? How valuable for the resource are external collaborations (e.g., with other childhood cancer survivor groups)? How likely are the proposed outreach activities to increase the role of the CCSS-based research findings in the updates of cancer survivor guidelines?

In addition, for applications involving clinical trials: Does the application adequately address the following, if applicable:

Study Design

Is the study design justified and appropriate to address primary and secondary outcome variable(s)/endpoints that will be clear, informative and relevant to the hypothesis being tested? Is the scientific rationale/premise of the study based on previously well-designed preclinical and/or clinical research? Given the methods used to assign participants and deliver interventions, is the study design adequately powered to answer the research question(s), test the proposed hypothesis/hypotheses, and provide interpretable results? Is the trial appropriately designed to conduct the research efficiently? Are the study populations (size, gender, age, demographic group), proposed intervention arms/dose, and duration of the trial, appropriate and well justified?

Are potential ethical issues adequately addressed? Is the process for obtaining informed consent or assent appropriate? Is the eligible population available? Are the plans for recruitment outreach, enrollment, retention, handling dropouts, missed visits, and losses to follow-up appropriate to ensure robust data collection? Are the planned recruitment timelines feasible and is the plan to monitor accrual adequate? Has the need for randomization (or not), masking (if appropriate), controls, and inclusion/exclusion criteria been addressed? Are differences addressed, if applicable, in the intervention effect due to sex/gender and race/ethnicity?

Are the plans to standardize, assure quality of, and monitor adherence to, the trial protocol and data collection or distribution guidelines appropriate? Is there a plan to obtain required study agent(s)? Does the application propose to use existing available resources, as applicable?

Data Management and Statistical Analysis

Are planned analyses and statistical approach appropriate for the proposed study design and methods used to assign participants and deliver interventions? Are the procedures for data management and quality control of data adequate at clinical site(s) or at center laboratories, as applicable? Have the methods for standardization of procedures for data management to assess the effect of the intervention and quality control been addressed? Is there a plan to complete data analysis within the proposed period of the award?

If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of individuals of all ages (including children and older adults), justified in terms of the scientific goals and research strategy proposed?

If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of individuals of all ages (including children and older adults), justified in terms of the scientific goals and research strategy proposed?


Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

In addition, for applications involving clinical trials: If proposed, are the administrative, data coordinating, enrollment and laboratory/testing centers, appropriate for the trial proposed? Does the application adequately address the capability and ability to conduct the trial at the proposed site(s) or centers? Are the plans to add or drop enrollment centers, as needed, appropriate? If international site(s) is/are proposed, does the application adequately address the complexity of executing the clinical trial? If multi-sites/centers, is there evidence of the ability of the individual site or center to: (1) enroll the proposed numbers; (2) adhere to the protocol; (3) collect and transmit data in an accurate and timely fashion; and, (4) operate within the proposed organizational structure?

Additional Review Criteria

As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.

Study Timeline

Is the study timeline described in detail, taking into account start-up activities, the anticipated rate of enrollment, and planned follow-up assessment? Is the projected timeline feasible and well justified? Does the project incorporate efficiencies and utilize existing resources (e.g., CTSAs, practice-based research networks, electronic medical records, administrative database, or patient registries) to increase the efficiency of participant enrollment and data collection, as appropriate?

Are potential challenges and corresponding solutions discussed (e.g., strategies that can be implemented in the event of enrollment shortfalls)?

Protections for Human Subjects

For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.

Inclusion of Women, Minorities, and Individuals Across the Lifespan

When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of individuals of all ages (including children and older adults) to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.

Vertebrate Animals

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.


Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.


Not Applicable


For Renewals, the committee will consider the progress made in the last funding period.


Not Applicable

Additional Review Considerations

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

Applications from Foreign Organizations

Not Applicable

Select Agent Research

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

Resource Sharing Plans

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: (1) Data Sharing Plan; (2) Sharing Model Organisms; and (3)  Genomic Data Sharing Plan (GDS).

Authentication of Key Biological and/or Chemical Resources:

For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.

Budget and Period of Support

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NCI, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

As part of the scientific peer review, all applications will receive a written critique.

Applications may undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.

Appeals of initial peer review will not be accepted for applications submitted in response to this FOA.

Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the National Cancer Advisory Board. The following will be considered in making funding decisions:

  • Scientific and technical merit of the proposed project as determined by scientific peer review.
  • Availability of funds.
  • Relevance of the proposed project to program priorities.

3. Anticipated Announcement and Award Dates

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.

Information regarding the disposition of applications is available in the NIH Grants Policy Statement.

Section VI. Award Administration Information

1. Award Notices

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee’s business official.

Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website.  This includes any recent legislation and policy applicable to awards that is highlighted on this website.

 Institutional Review Board or Independent Ethics Committee Approval: Grantee institutions must ensure that protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the awardee must provide NIH copies of documents related to all major changes in the status of ongoing protocols.

Data and Safety Monitoring Requirements: The NIH policy for data and safety monitoring requires oversight and monitoring of all NIH-conducted or -supported human biomedical and behavioral intervention studies (clinical trials) to ensure the safety of participants and the validity and integrity of the data. Further information concerning these requirements is found at and in the application instructions (SF424 (R&R) and PHS 398). Investigational New Drug or Investigational Device Exemption Requirements: Consistent with federal regulations, clinical research projects involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices for a purpose other than that for which they were licensed) in humans under a research protocol must be performed under a Food and Drug Administration (FDA) investigational new drug (IND) or investigational device exemption (IDE)." NIH is requiring data sharing for all COVID-19 projects, where it is not prohibited (i.e., Tribal data sovereignty). The NIH expects and supports the timely release and sharing of final research data from NIH-supported studies for use by other researchers to expedite the translation of research results into knowledge, products, and procedures to improve human health. Grantees are expected to work with the RADx-rad DCC to submit common evaluation metrics on COVID-19 testing-related outcomes and implementation to the DCC. Grantees should identify a dedicated unit responsible for these data reporting activities. NIH expects that all projects funded under this FOA will actively coordinate, collaborate, and share data with the RADx-rad DCC, as allowed, and with considerations under tribal IRB processes, as appropriate. Researchers applying to this funding opportunity are strongly encouraged to review the DCC funding opportunity. To the extent possible, data acquisition, collection, and curation strategies should be coordinated with the DCC guidance for annotation and benchmarking of data, including obtaining appropriate consent for data sharing and implementation of the schemas proposed under the ABOUT ML effort (“Annotation and benchmarking on understanding and transparency for machine learning lifecycles”; available at Grantees are expected to participate in DCC-organized activities, including regular (e.g., monthly) progress meetings with individual or subsets of awardees, and twice annual meetings with all RADx-rad awardees.

2. Administrative and National Policy Requirements

All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.

Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age and, in some circumstances, religion, conscience, and sex. This includes ensuring programs are accessible to persons with limited English proficiency. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. Please see and

HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research. For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA.

Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at or call 1-800-368-1019 or TDD 1-800-537-7697.

In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant’s integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 “Federal awarding agency review of risk posed by applicants.” This provision will apply to all NIH grants and cooperative agreements except fellowships.

Cooperative Agreement Terms and Conditions of Award

The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (DHHS) grant administration regulations at 45 CFR Parts 75, and other HHS, PHS, and NIH grant administration policies.

The administrative and funding instrument used for this program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the role of the NIH is to work in a partnership with the award recipients to support and stimulate their research; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the awardees for the project as a whole, although specific tasks and activities may be shared among the awardees and the NIH as defined below.

The PD(s)PI(s) will have the primary responsibility for:

  • Defining the research plan and goals;
  • Overseeing the execution of the program as a whole;
  • Coordinating/overseeing research design, the development of a common study protocols for involvement of participants, and other research activities;
  • Ensuring compliance of the CCSS with the mandatory regulations (including protection of human subjects);
  • Overseeing the preparation of key study documents, including questionnaires, medical record abstract forms, and field procedures manuals;
  • Overseeing establishment and maintenance of quality control in all data and materials collection and management procedures;
  • Chairing the CCSS Steering Committee;
  • Cooperating with NCI programmatic, technical and administrative staff;
  • Implementing the recommendations of the CCSS Steering Committee to the extent consistent with the applicable grant regulations; and
  • Administratively managing the U24 award.

Awardees will retain custody of and have primary rights to the data and software developed under these awards, subject to Government rights of access consistent with current DHHS, PHS, and NIH policies.

Awardee institution and all participating institutions will be responsible for ensuring that the design, conduct, and/or reporting of research conducted by CCSS are not biased by any conflicting financial conflict of interests of an investigator. Awardees will be expected to implement appropriate policy and procedures on financial Conflict of Interest (COI).

NIH staff will have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:

A designated NCI Program Director(s) acting as a Project Scientist(s) will have the following responsibilities:

  • Participating in the activities of CCSS Steering Committee;
  • Providing technical assistance and advice to the awardees as appropriate (e.g., assisting in the development of the research protocols and/or interpretation and reporting of the collected information);
  • Monitoring progress of the resource as a whole and specific studies conducted.
  • Conducting periodic site visits for discussions with awardee research teams, observation of field data collection and management techniques, other matters;
  • Coordinating interactions, as appropriate and needed, with the NCI-supported Children's Oncology Group especially in data retrieval from exiting databases;
  • Facilitating interactions/collaborations between the awardees and other NCI-sponsored programs, investigators, or organizations that may contribute to the CCSS goals;
  • Serving as a liaison between the CCSS awardees and NCI staff members and investigators that may provide addition expertise and/or resources to the program;
  • Monitoring the adherence of the awardees to the approved data sharing plans.
  • Approve changes in the institutional membership based on recommendations from the CCSS PD(s)/PI(s).

The NCI reserves the right to adjust funding, withhold, suspend, or terminate the support to the awardee if the team is unable to meet the performance requirements set forth in these Terms and Conditions of Award, or significantly lower the level of performance.

Additional NCI staff members may be designated to have substantial involvement.

In addition, a NCI Program Director acting as the Program Official will be responsible for the normal scientific and programmatic stewardship and programmatic stewardship of the award, and will be named in the award notice.

Areas of Joint Responsibility include:

The Steering Committee will serve as the main governing board for CCSS. The CCSS Steering Committee will consist of the following voting members:

  • PD/PI and a designated senior investigator [or two PD(s)/PI(s) if multiple PDs/PIs option is used];
  • 1 or 2 Working Group chairs;
  • 1 or 2 representatives of the support functional groups and other members as deemed necessary by the Chair of the Steering Committee; and
  • Two NCI representatives.

Each voting member will have one vote, except for the NCI representatives, who will collectively have one vote. The Steering Committee will be chaired by the CCSS contact PD/PI. In the absence of the contact PD/PI, the second CCSS PD/PI (or a designated senior investigator) will chair Steering Committee meeting.

The Steering Committee may include additional individuals as non-voting members and may also form subcommittees as needed. One subcommittee should consist of external (non-affiliated with CCSS) researchers, who are experts in the field to advise the PD(s)/PI(s) and Steering Committee. Steering Committee may decide to continue with the current structure of committees or subcommittees or change this structure to better fit CCSS needs.

The Steering Committee will conduct one face to face meeting a year with additional teleconferences or meetings as needed.

The Steering Committee will be responsible for any changes to the CCSS organizational structure and Standard Operating Procedures. The Steering Committee will have primary responsibility to establish priorities, and to develop and provide preliminary approval of projects (including young pilot projects) and or protocols.

The Steering Committee will review on a regular basis:

  • the overall performance of the CCSS;
  • the performance of specific functional support groups; and
  • the performance of investigator/teams at institutions participating in the Consortium.

The CCSS Steering Committee will have the authority to place on probation and to suspend participating institutions and add new institutions as participants, if appropriate. The CCSS Steering Committee will evaluate and approve all potential treatment (intervention) concepts as well as correlative science proposals, formally presented either by members of CCSS (internal investigators) or by outside investigators using CCSS resources.

Dispute Resolution:

Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened. It will have three members: a designee of the Steering Committee chosen without NIH staff voting, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual awardee. This special dispute resolution procedure does not alter the awardee's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and DHHS regulation 45 CFR Part 16.

3. Reporting

When multiple years are involved, awardees will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement.

A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later.  All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at on all subawards over $25,000.  See the NIH Grants Policy Statement for additional information on this reporting requirement.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period.  The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS).  This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313).  As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available.  Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 – Award Term and Conditions for Recipient Integrity and Performance Matters.

Section VII. Agency Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

Application Submission Contacts

eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten submission by the due date, and post-submission issues)

Finding Help Online: (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources)
Email: (preferred method of contact)
Telephone: 301-945-7573 Customer Support (Questions regarding registration and Workspace)
Contact Center Telephone: 800-518-4726

Scientific/Research Contact(s)

Nita L. Seibel, MD
National Cancer Institute (NCI)
Telephone: 240-276-6078

Peer Review Contact(s)

Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: ncirefof@dea.nci/

Financial/Grants Management Contact(s)

Shane Woodward
National Cancer Institute (NCI)
Telephone: 240-276-6303

Section VIII. Other Information

Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Authority and Regulations

Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75.

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
NIH Office of Extramural Research Logo
Department of Health and Human Services (HHS) - Home Page
Department of Health
and Human Services (HHS) - Government Made Easy
NIH... Turning Discovery Into Health®

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.